Lantern Pharma, Inc. (NASDAQ: LTRN) is a clinical-stage biopharmaceutical company that leverages artificial intelligence and genomic data to accelerate the discovery and development of targeted oncology therapies. The company’s proprietary RADR® (Response Algorithm for Drug Development) platform integrates machine learning and large-scale genomic profiling to identify patient populations most likely to benefit from existing and novel drug candidates. By focusing on precision oncology, Lantern Pharma aims to streamline development timelines, reduce costs and improve clinical outcomes for patients with hard-to-treat cancers.
Lantern Pharma’s pipeline includes several lead assets at various stages of development. LP-184 is an experimental small molecule designed for patients with glioblastoma and pancreatic cancer, advancing through preclinical studies with biomarker-driven patient selection. LP-300 is being evaluated in non–small cell lung cancer with a focus on improving outcomes in patients who have developed resistance to first-line therapies. In addition, LP-284 is progressing through early-stage trials targeting hematologic malignancies and solid tumors characterized by DNA damage repair deficiencies.
Research and development activities are conducted primarily at the company’s facilities in Dallas, Texas, with additional data science and computational biology teams in Austin. Lantern Pharma collaborates with academic institutions, contract research organizations and strategic partners to enrich its translational research efforts. The RADR® platform continuously mines real-world evidence, clinical trial data and molecular profiles to inform go/no-go decisions, optimize trial design and identify novel indications for Lantern’s therapeutic candidates.
Founded in 2016 and headquartered in Dallas, Lantern Pharma is led by President and Chief Executive Officer Jonathan Ayers, whose background spans both biotech leadership and pharmaceutical R&D. The company’s management team combines expertise in drug discovery, clinical development and regulatory affairs, supporting Lantern Pharma’s mission to transform oncology drug development through the integration of artificial intelligence and precision medicine.
AI Generated. May Contain Errors.
